Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 8;18(9):1936.
doi: 10.3390/ijms18091936.

Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study

Affiliations

Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study

Gloria Romagnoli et al. Int J Mol Sci. .

Abstract

Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune microenvironment and have been shown to provide prognostic and predictive biomarkers. The extent of lymphocytic infiltration in tumor tissues can be assessed by evaluating hematoxylin and eosin (H&E)-stained tumor sections. We investigated tissue microarrays of 31 invasive breast cancer patients, looking at quantity and topological distribution of CD3+, CD8+, CD20+, Ki67+, FoxP3+ TILs and CD3+/FoxP3+, CD8+/FoxP3+ cell ratios. We separately evaluated TILs at the invasive edge and at the center of the tumor, to find any clinical implications of tumor heterogeneity. No statistically significant difference was found in quantity and distribution of both TIL subsets and TIL ratios, by comparing patients who suffered from a local or distant recurrence of the tumor (relapse group: 13 patients) with patients not showing cancer relapse (non-relapse group: 18 patients). In the whole sample, we observed three main statistically significant positive correlations: (1) between CD3+ and CD8+ T-cells; (2) between FoxP3+ and Ki67+ lymphocyte infiltration; (3) between CD3+/FoxP3+ cell ratio (C3FR) and CD8+/FoxP3+ cell ratio (C8FR). Tumor heterogeneity and stronger positive TIL associations were found in the non-relapse group, where both CD3-CD8 and FoxP3-Ki67 inter-correlations were found to be significant at the center of the tumor, while the correlation between C3FR and C8FR was significant at the invasive edge. No correlations between TIL subsets were detected in the relapse group. Our findings suggest the existence of stronger inter-subtype lymphocytic networks in invasive breast cancer not showing recurrence. Further evaluations of clinical and topological correlations between and within TIL subsets are needed, in addition to the assessment of TIL quantification and distribution, in order to follow up on whether morphological evaluation of TILs might reveal the underlying lymphocytic functional connectivity and help relapse prediction.

Keywords: CD3; CD3/FoxP3 ratio; CD8; CD8/FoxP3 ratio; FoxP3; breast cancer; regulatory T cells (Tregs); tumor heterogeneity; tumor immunogenicity; tumor-infiltrating lymphocytes (TILs).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Representative examples of the immunohistochemical staining of the lymphocyte markers CD20, CD3, CD8, FoxP3, Ki67, for normal breast epithelium, DCIS and invasive breast cancer, the latter divided in tumor center and margin.
Figure 2
Figure 2
Scatterplot matrix (SPLOM) of correlations betweendifferent TIL subsets (CD8+, CD3+, Ki67+, FoxP3+, CD20+), CD3+/FoxP3+ (C3FR) and CD8+/FoxP3+ (C8FR) cell ratios. Histograms of the variables are shown in the diagonal. Only for SPLOM purposes, missing values were excluded listwise, to obtain a consistent case base for the chart. * Correlation is significant at the 0.05 level (2-tailed). ** Correlation is significant at the 0.01 level (2-tailed).

References

    1. Baldassarre G., Belletti B. Molecular biology of breast tumors and prognosis. F1000Res. 2016;5:711. doi: 10.12688/f1000research.8158.1. - DOI - PMC - PubMed
    1. Alkatout I., Order B., Klapper W., Weigel M.T., Jonat W., Schaefer F.K., Mundhenke C., Wenners A. Surgical impact of new treatments in breast cancer. Minerva Ginecol. 2013;65:363–383. - PubMed
    1. Mathot L., Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: A deeper understanding. Cancer Sci. 2012;103:626–631. doi: 10.1111/j.1349-7006.2011.02195.x. - DOI - PMC - PubMed
    1. Fidler I.J. The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer. 2003;3:453–458. doi: 10.1038/nrc1098. - DOI - PubMed
    1. Luen S.J., Savas P., Fox S.B., Salgado R., Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017;49:141–155. doi: 10.1016/j.pathol.2016.10.010. - DOI - PubMed

MeSH terms